

Sexually Transmitted Diseases

Capital Conference, June 2005
Gregory Perron
MAJ USAF MC
Faculty Family Physician

Introduction

- Diseases Covered
 - Genital Ulcer Disease
 - HSV, syphilis
 - HPV
 - Urethritis/Cervicitis
 - GC, Chlamydia, NGU, MPC
 - Vaginal Discharge
 - BV, trichomonas
- Not Covered
 - HIV, Chancroid, LGV
- Future Trends

Useful Resources

CDC: Center for Disease Control
Sexually Transmitted Diseases Treatment
Guidelines, 2002

<http://www.cdc.gov/std/treatment/TOC2002TG.htm>

AHRQ / US Preventive Services Task Force:

[http://www.ahrq.gov/clinic/uspstf/uspstopics.
htm](http://www.ahrq.gov/clinic/uspstf/uspstopics.htm)

Genital Ulcer Diseases

- Differential includes:
 - HSV-1 vs HSV-2 : most common in US
 - Primary Syphilis
 - Things You Won't See On Boards:
 - Chancroid
 - LGV-- lymphogranuloma venereum
 - Granuloma Inguinale
 - See handout or CDC if esoterica is your thing

Herpes Simplex Virus


- Recurrent, incurable viral disease
- HSV-1 and HSV-2: Over 50 million affected patients in US; ~1 million new cases/year
- Most HSV-2 infections undiagnosed
- Most transmission from undiagnosed or asymptomatic pts
- KEY: Diagnose by clinical suspicion and **type-specific testing** (e.g. culture or DFA)- not Tzank

HSV, Primary Infection

- 5-30% due to HSV1
- HSV-2 mostly anogenital
- Patient Education:
 - a. Natural history of disease
 - b. Sexual & perinatal transmission
 - c. Methods to reduce risk of transmission



Primary HSV, female patient



Primary infection in pregnancy:
highest risk of fetal transmission

Medical Treatment

First Clinical Episode

Recommended Regimens

Acyclovir 400 mg po tid x 7-10 days,
OR

Acyclovir 200 mg po 5x/day for 7-10
days,

OR

Famciclovir 250 mg po tid x 7-10 days,
OR

Valacyclovir 1 gm po bid x 7-10 days.


HSV – Recurrent Episodes

- HSV-2 significant more likely to recur
- Recurrent episodes less severe than initial
- Episodic Treatment:
 - Acyclovir 400 TID or 200 5X/Day or 800 BID X 5days
 - Famvir 125 BID X 5 days
 - Valacyclovir 500 BID X 3 days

HSV Suppression

- Suppression in pregnancy not routinely suggested by ACOG or CDC
- Reduces frequency of clinical flares by 70-80%, significantly reduces shedding
 - Acyclovir 400 BID
 - Famvir 250 BID
 - Valacyclovir 500mg-1000mg QD
 - Start at 36 wks in pregnancy, or if recurrent episodes

Meanwhile in the Lab



Syphilis - *Treponema pallidum*

- Systemic disease caused by *T. pallidum*
- 4 Stages of infection
 - Primary
 - Secondary
 - Tertiary
 - Latent



Primary syphilis-chancere



Hallmark:
PAINLESS!



Secondary syphilis



-skin rash; mucocutaneous lesions,
regional lymphadenopathy

Secondary syphilis - condyloma lata



Syphilis Stages cont

- **Tertiary**- cardiac, neurologic, ophthalmic, auditory, gummatous lesions
- **Latent**- active infection diagnosed by serology without clinical signs of infection
 - **Early Latent**- infection acquired within preceding year
 - **Late Latent**- infection acquired >1 yr ago
 - **Syphilis of Unknown Duration**- self explanatory

Syphilis- Diagnostic Testing

- Treponemal Tests
 - Darkfield exam
 - Direct Fluorescent Antibody Tests
- Nontreponemal Tests
 - Venereal Disease Research Laboratory (VDRL)
 - RPR
- Diagnosis – mix of clinical/diagnostic

Treponemal Tests

- Fluorescent Treponemal Antibody Absorbed (FTA-ABS)
 - CSF FTA-ABS highly sensitive for neurosyphilis
(a negative test excludes neurosyphilis)
- Microhemagglutination Assay for Antibody to *T. pallidum* (MHA-TP)
 - Most patients positive for remainder of their lives; poor marker for disease activity

Syphilis Treatment


- Three Drugs
 - Penicillin First line; Doxy/TCN 2nd line
 - Desensitize in pregnancy and use penicillin
- Treatment duration and course varies with syphilis stage
 - Unlikely to be on boards; see handout or CDC for details



www.dilbert.com scottadams@aol.com



4-20-05 ©2005 Scott Adams, Inc./Dist. by UFS, Inc.



© Scott Adams, Inc./Dist. by UFS, Inc.

Urethritis/Cervicitis Diseases

- Chlamydia
- GC
- MPC (mucopurulent cervicitis)
- NGU (nongonococcal urethritis)

Chlamydia

- Approximately 3 million cases / year!
- Asymptomatic infection common in women, less common in men
- Complications: infertility, PID, ectopic pregnancy

USPSTF-Chlamydia Screening

- A: Sexually active women <25, others with individual/population risk factors (new/multiple partners; prev GC; other STD, inconsistent condom use, sex worker, drug user)
- C: Screening asymptomatic low-risk women including in pregnancy
- B: Pregnant, <25 or increased risk
- I: Asymptomatic men

Chlamydia Diagnosis

- Culture- historical “gold standard”
 - Rarely recommended now
 - Limited medicolegal role
- Antigen detection with EIA acceptable
- DNA amplification testing
 - PCR, Ligase Chain Reaction – urine or cervical

Chlamydia Treatment

- Direct Observed Therapy Best!
 - Azithromycin 1gm po X 1
- Doxycycline 100mg BID X 7 days
- Alternatives:
 - Erythromycin 500 QID X 7D
 - EES 800 QID X 7D
 - Ofloxacin 300BID X 7D
 - Levofloxacin 500 QD X 7D
- ALL: Treat sexual partner; screen for other STDs
- counsel patients to abstain from sex until 7 days after patient and partner treated

Chlamydia in Pregnancy

- Screen all women in 1st trimester, selective screening in 3rd trimester for high-risk
- Treat with
 - Azithromycin 1gm X single dose
 - erythromycin 500 QID X 7D
 - amoxicillin 500 TID X 7d
 - Treat partners; abstain from sex until 7 weeks after treatment & partner treated
- Test of Cure in 3 weeks recommended!

Chlamydia Followup

- Test of Cure: recommended if doxy/azithro not used, and in pregnancy
- Rescreen: Test for REINFECTION
 - test 3-4 months later, definitely by 12 months after diagnosis
 - urine chlamydia testing ideal
- Test for other STD's

Gonorrhea



ick

- 116.2 cases:100,000
- 2nd most common reportable disease
- Men typically symptomatic
- Women often asymptomatic
- Complications: epididymitis, PID, infertility, ectopic pregnancy

USPSTF Screening Rec's


- B: Screen all sexually active women/pregnant women if they are young (<25) or have individual/population risk factors (new/multiple partners; prev GC; other STD, inconsistent condom use, sex worker, drug user)
- I: No recommendation for asymptomatic men
- D: Against screening for low risk individuals
- I: Low-risk pregnant women
- A: Eye Prophylaxis for neonates

Gonococcal cervicitis

- Diagnose with DNA probe or culture
 - CO₂-rich environment for culture
- **Cannot** diagnose in women with gram stain



Gonorrhea - gram stain of urethral discharge



Diagnosis by gram stain- MEN only

GC Treatment

- Ceftriaxone 125mg IM
- Cipro 500, oflox 400, levo 250 PO
 - NOT INDICATED for: infection acquired in California, Hawaii, Pacific Islands, Asia; England; any patient or partner of MSM (men who have sex with men); check local trends
- (cefixime 400mg PO)

Co-Treat for Chlamydia?

- Classically, diagnosis of GC = treatment for both GC and chlamydia
- Clinical practice still often follows this
- CDC recommends presumptive treatment unless concurrent highly accurate testing for chlamydia is negative

MPC, NGU

- MPC- mucopurulent cervicitis
- Dx: mucopurulent discharge from os or on endocervical swab.
- ? Value of increased PMN's on endocervical gram stain
- Test for GC, Chlamydia
- Consider empiric Rx
- NGU- nongonococcal urethritis
- Dx: urethral smear w/ >5WBC/hpf; no GNID; clinical hx of discharge
- RX: 1gm azithro or doxy 100 BID X 7d
- Test for GC ,Chlamydia

DOCTOR FUN

10 Nov 2000



"We've gotten a rather disturbing report back from product testing."

Copyright © 2000 David Farley, d-farley@ibiblio.org
<http://ibiblio.org/Dave/drfun.html>

This cartoon is made available on the Internet for personal viewing only. Opinions expressed herein are solely those of the author.

Human Papilloma Virus

HPV: > 30 types in
anogenital
infection

Visible warts: 6/11

Cervical dysplasia:
especially 16/18

Diagnosis: clinical
exam



HPV Counselling



- Asymptomatic/Subclinical disease is common
- Once you've got it, you've got it!
- Counsel re: link to dysplasia; transmissibility; regular pap testing
- No role for HPV typing or routine colposcopy for visible warts

HPV- Treatment

- Patient-applied
 - Podophlox 0.5% BID X 3 days, off 4 days, repeat up to 4 cycles.
 - Inimiquod 5% cream QHS, 3X/wk, 16wks max, wash off 6-10 hrs later
- Provider-applied
 - LN2 Q 1-2 wks
 - (Podophyllin resin 10-25%)
 - (TCA 80-90%, weekly)
 - (Laser therapy)
- Suggest referral for meatal warts, laryngeal warts



Diseases Characterized by Vaginal Discharge


- Vulvovaginal Candidiasis
- Bacterial Vaginosis
- Trichomonas vaginitis
- Recommend targeted history, exam, KOH, wet prep, vaginal pH. Consider also GC/Chlamydia testing, esp. if WBC's seen



Trichomonas

- motile, pear-shaped, 10 μm by 7 μm , organisms with visible flagella. Wet prep only ~60-70% sensitive
- + whiff test; WBC's on wet prep; vaginal pH >4.5
- Trich on thin prep pap has >90% accuracy
- Diffuse, yellow-green, malodorous discharge
- Treat with metronidazole 2gm PO X 1
 - 500 BID X 7D alternative dosing
- Treat sexual partner

Bacterial Vaginosis



- Homogeneous vaginal discharge (color and amount may vary)
- Presence of clue cells (greater than 20%)
- Amine (fishy) odor when potassium hydroxide solution is added to vaginal secretions ("whiff test")
- Vaginal pH greater than 4.5
- Absence of the normal vaginal lactobacilli
- 3+ above criteria for diagnosis.
- *Vaginosis* – not *Vaginitis*

Bacterial Vaginosis Treatment


- Treatment Regimens:
 - Metronidazole 500 BID PO X 7D
 - Metronidazole 2gm PO X 1 dose
 - Metronidazole gel 0.75% IVA BID X 5D
 - Clindamycin 300mg PO BID X 7D
 - Clindamycin 2% cream 5GM IVA QHS X7D
- Recurrence is common
- Treatment of sexual partners not suggested

Vaccines for STDs

- Hepatitis A: MSM (men who have sex with men); illicit drug users, patients with chronic liver disease
- Hepatitis B: as per hepA, plus all teenagers; all treated for an STD; household contacts of chronic hep B patients
- Future Trends: HPV, HSV-2 vaccines


Questions?

THAT CONCLUDES MY
TWO-HOUR PRESENTA-
TION. ANY QUESTIONS?



www.dilbert.com scottadams@aol.com

DID YOU INTEND THE
PRESENTATION TO BE
INCOMPREHENSIBLE,
OR DO YOU HAVE SOME
SORT OF RARE "POWER-
POINT" DISABILITY?



8/16/03 © 2003 United Feature Syndicate, Inc.

ARE THERE
ANY QUESTIONS
ABOUT THE
CONTENT?



THERE WAS
CONTENT?

